The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility. The particle-size distribution of a pharmaceutical granulation is ...
Although physicochemical preformulation screening is practised universally within the pharmaceutical industry, physicomechanical screening is applied to a lesser extent and often only where a problem ...
This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...
BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...
Alderley Park, UK - 16 November 2022: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, further to the announcement on 12 ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
The FDA approved a new tablet formulation of Brukinsa for five cancer indications, simplifying dosing to two 160 mg tablets daily. Brukinsa is the only BTK inhibitor offering flexible dosing and ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback